8-K: Evolent Health Reports Q1 2026 Results, Reaffirms Guidance

Evolent Health announced its first quarter 2026 financial results, reporting increased revenue and a reduced net loss, while reaffirming its full-year guidance.

Summary

• Evolent Health reported revenue of $496.2 million for the first quarter of 2026, an increase from $483.6 million in the same period of 2025.
• The company reported a net loss attributable to common shareholders of $26.6 million for Q1 2026, an improvement from a net loss of $72.3 million in Q1 2025.
• Adjusted EBITDA for Q1 2026 was $22.1 million, down from $36.9 million in Q1 2025.
• The company reaffirmed its full-year 2026 revenue guidance of $2.4 billion to $2.6 billion and Adjusted EBITDA guidance of $110 million to $140 million.
• Two new revenue agreements were announced: an advanced imaging solution expected to go live in Q3 2026 and an expansion of Oncology and Cardiology solutions expected to generate over $200 million in annual revenue.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While revenue growth and a reduced net loss are positive, the decline in Adjusted EBITDA and increased medical expense ratio present challenges. The reaffirmation of guidance and new contract wins offer some optimism.

Positives

• Revenue increased to $496.2 million in Q1 2026 from $483.6 million in Q1 2025.
• Net loss attributable to common shareholders significantly decreased to $26.6 million in Q1 2026 from $72.3 million in Q1 2025.
• Net loss margin improved to (5.4)% in Q1 2026 from (14.9)% in Q1 2025.
• Two new significant revenue agreements were signed, including one expected to generate over $200 million in annual revenue.
• Successful, on-time oncology launches at Highmark and Aetna were reported.
• The company is on track with its plan for the year.

Negatives

• Adjusted EBITDA decreased to $22.1 million in Q1 2026 from $36.9 million in Q1 2025.
• Adjusted EBITDA Margin decreased to 4.4% in Q1 2026 from 7.6% in Q1 2025.
• The Medical Expense Ratio increased to 93.3% in Q1 2026 from 68.0% (or 84.0% excluding Evolent Care Partners) in Q1 2025.
• Average Lives on Platform/Cases decreased across all reported suites and administrative services compared to Q1 2025.
• Average PMPM Fees/Revenue per Case decreased for Specialty Technology and Services Suite and Administrative Services.

Risks

• The significant portion of revenue derived from largest partners, and the potential loss, termination, or renegotiation of contracts with significant partners.
• Increasing number of risk-sharing arrangements entered into with partners.
• Growth and success of partners are subject to factors outside of Evolent's control, including governmental funding reductions and policy changes.
• Ability to accurately predict exposure under performance-based contracts.
• Failure by customers to provide accurate and timely information.
• Ability to recover upfront costs in partner relationships and develop them over time.
• Competition could limit Evolent's ability to maintain or expand market share.
• Evolution of the healthcare regulatory and political framework.

Future Outlook

Evolent Health is reiterating its full-year 2026 guidance, expecting revenue between $2.4 billion and $2.6 billion and Adjusted EBITDA between $110 million and $140 million. The company also anticipates deploying approximately $25 million to $30 million in cash for capitalized software development during 2026.

Management Comments

• "I am happy with the strong start to the year. We are on track with our plan and have had successful, on-time oncology launches at both Highmark and Aetna."
• "As we look into 2027 and beyond, we remain focused on both extending our market leadership in oncology and addressing the big opportunity we have with AI, all while fulfilling our commitments to shareholders, employees and customers."

Industry Context

StockSavvy.ai notes that Evolent Health's results reflect the ongoing demand for complex specialty care solutions driven by rising medical costs impacting health plans. The company's focus on oncology and the strategic integration of AI align with broader industry trends towards value-based care and technological innovation.

Stakeholder Impact

• Shareholders: Reaffirmed guidance and new contract wins may be viewed positively, but declining Adjusted EBITDA and increased medical costs could be concerns.
• Employees: Management's focus on fulfilling commitments to employees is noted.
• Customers (Health Plans/Providers): Evolent's solutions aim to simplify healthcare and improve outcomes, potentially benefiting customers through cost management and better patient care.
• Suppliers: No specific impact mentioned.

Next Steps

• Advanced imaging solution expected to go live in the third quarter, subject to state regulatory approvals.
• Expansion of Oncology and Cardiology solutions scheduled to go live in the third quarter, subject to regulatory approvals.
• Conference call to discuss financial performance held on May 7, 2026.

Key Dates

Recommendation

The company shows revenue growth and a reduced net loss, along with new contract wins that are expected to contribute significantly to future revenue. However, the decrease in Adjusted EBITDA and the rise in the Medical Expense Ratio indicate operational pressures. The reaffirmation of full-year guidance provides some stability, but the mixed financial signals warrant a cautious 'hold' approach pending further clarity on margin improvement and cost management.

Keywords

Evolent Health, Q1 2026 Results, Healthcare Solutions, Specialty Care, Oncology, Adjusted EBITDA, Revenue Growth, Financial Report